208 related articles for article (PubMed ID: 23494984)
1. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M; Lubomirov R; Fayet-Mello A; Aouri M; Rotger M; Buclin T; Widmer N; Gatri M; Ledergerber B; Rentsch K; Cavassini M; Panchaud A; Guidi M; Telenti A; Décosterd LA; Csajka C;
J Antimicrob Chemother; 2014 Sep; 69(9):2489-98. PubMed ID: 24821595
[TBL] [Abstract][Full Text] [Related]
3. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics.
Calcagno A; Yilmaz A; Cusato J; Simiele M; Bertucci R; Siccardi M; Marinaro L; D'Avolio A; Di Perri G; Bonora S
AIDS; 2012 Jul; 26(12):1529-33. PubMed ID: 22555164
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.
Moltó J; Barbanoj MJ; Miranda C; Blanco A; Santos JR; Negredo E; Costa J; Domingo P; Clotet B; Valle M
Clin Pharmacokinet; 2008; 47(10):681-92. PubMed ID: 18783298
[TBL] [Abstract][Full Text] [Related]
5. Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.
Cattaneo D; Gervasoni C; Cozzi V; Baldelli S; Fucile S; Meraviglia P; Landonio S; Boreggio G; Rizzardini G; Clementi E
Pharmacol Res; 2012 Feb; 65(2):198-203. PubMed ID: 21958880
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment.
Sekar V; Spinosa-Guzman S; De Paepe E; Stevens T; Tomaka F; De Pauw M; Hoetelmans RM
Clin Pharmacokinet; 2010 May; 49(5):343-50. PubMed ID: 20384396
[TBL] [Abstract][Full Text] [Related]
7. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.
Zorrilla CD; Wright R; Osiyemi OO; Yasin S; Baugh B; Brown K; Coate B; Verboven P; Mrus J; Falcon R; Kakuda TN
HIV Med; 2014 Jan; 15(1):50-6. PubMed ID: 23731450
[TBL] [Abstract][Full Text] [Related]
8. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin.
Aquilante CL; Kiser JJ; Anderson PL; Christians U; Kosmiski LA; Daily EB; Hoffman KL; Hopley CW; Predhomme JA; Schniedewind B; Sidhom MS
J Clin Pharmacol; 2012 Nov; 52(11):1725-38. PubMed ID: 22174437
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
Lê MP; Chaix ML; Chevret S; Bertrand J; Raffi F; Gallien S; El Abbassi EMB; Katlama C; Delobel P; Yazdanpanah Y; Saillard J; Molina JM; Peytavin G;
J Antimicrob Chemother; 2018 Aug; 73(8):2120-2128. PubMed ID: 29905808
[TBL] [Abstract][Full Text] [Related]
10. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of darunavir/ritonavir in Asian HIV-1-infected children aged ≥7 years.
Chokephaibulkit K; Prasitsuebsai W; Wittawatmongkol O; Gorowara M; Phongsamart W; Sophonphan J; Kerr SJ; Vanprapar N; Puthanakit T; Pasomsap C; Suwanlerk T; Sekar V; Burger D; Ananworanich J;
Antivir Ther; 2012; 17(7):1263-9. PubMed ID: 22954687
[TBL] [Abstract][Full Text] [Related]
12. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.
Kohlrausch FB; de Cássia Estrela R; Barroso PF; Suarez-Kurtz G
Br J Clin Pharmacol; 2010 Jan; 69(1):95-8. PubMed ID: 20078617
[TBL] [Abstract][Full Text] [Related]
13. Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients.
Moltó J; Valle M; Miranda C; Cedeño S; Negredo E; Barbanoj MJ; Clotet B
Antimicrob Agents Chemother; 2011 Jan; 55(1):326-30. PubMed ID: 21078942
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.
Barrail-Tran A; Yazdanpanah Y; Goldwirt L; Chêne G; Colin C; Piketty C; Bollens D; Katlama C; Descamps D; Molina JM; Fagard C; Taburet AM;
AIDS; 2010 Oct; 24(16):2581-3. PubMed ID: 20960678
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.
Kappelhoff BS; Huitema AD; Crommentuyn KM; Mulder JW; Meenhorst PL; van Gorp EC; Mairuhu AT; Beijnen JH
Br J Clin Pharmacol; 2005 Feb; 59(2):174-82. PubMed ID: 15676039
[TBL] [Abstract][Full Text] [Related]
16. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R; di Iulio J; Fayet A; Colombo S; Martinez R; Marzolini C; Furrer H; Vernazza P; Calmy A; Cavassini M; Ledergerber B; Rentsch K; Descombes P; Buclin T; Decosterd LA; Csajka C; Telenti A;
Pharmacogenet Genomics; 2010 Apr; 20(4):217-30. PubMed ID: 20139798
[TBL] [Abstract][Full Text] [Related]
17. Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.
Colbers A; Greupink R; Litjens C; Burger D; Russel FG
Clin Pharmacokinet; 2016 Mar; 55(3):381-96. PubMed ID: 26369773
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.
Boffito M; Miralles D; Hill A
HIV Clin Trials; 2008; 9(6):418-27. PubMed ID: 19203907
[TBL] [Abstract][Full Text] [Related]
19. Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.
Cressey TR; Urien S; Hirt D; Halue G; Techapornroong M; Bowonwatanuwong C; Leenasirimakul P; Treluyer JM; Jourdain G; Lallemant M;
Ther Drug Monit; 2011 Feb; 33(1):25-31. PubMed ID: 21233689
[TBL] [Abstract][Full Text] [Related]
20. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
AIDS; 2000 Jun; 14(9):F103-10. PubMed ID: 10894270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
